Scinai Immunotherapeutics Stock Performance
| SCNI Stock | USD 0.75 0.01 1.32% |
The entity has a beta of 3.39, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Scinai Immunotherapeuti will likely underperform. At this point, Scinai Immunotherapeutics has a negative expected return of -0.66%. Please make sure to validate Scinai Immunotherapeuti's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Scinai Immunotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Scinai Immunotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:10 | Last Split Date 2024-05-21 |
1 | Is Scinai Immunotherapeutics Ltd. stock supported by free cash flow - Portfolio Return Summary Precise Buy Zone Tips - newser.com | 10/23/2025 |
2 | How Scinai Immunotherapeutics Ltd. stock compares with market leaders - 2025 Dividend Review Stepwise Trade Execution Plans - newser.com | 10/30/2025 |
3 | Scinai Immunotherapeutics Announces December 2025 Shareholder Meeting - TipRanks | 11/13/2025 |
4 | Will Scinai Immunotherapeutics Ltd. stock split increase liquidity - Market Sentiment Review Technical Entry and Exit Alerts - newser.com | 11/19/2025 |
5 | How Scinai Immunotherapeutics Ltd. stock reacts to new regulations - Weekly Volume Report Weekly High Conviction Ideas - Newser | 12/04/2025 |
6 | Gap Down How analysts revise price targets for Scinai Immunotherapeutics Ltd. stock - Earnings Risk Summary High Accuracy Trade Alerts - ulpravda.ru | 12/19/2025 |
| Begin Period Cash Flow | 5 M | |
| Total Cashflows From Investing Activities | -12 K |
Scinai Immunotherapeuti Relative Risk vs. Return Landscape
If you would invest 132.00 in Scinai Immunotherapeutics on September 26, 2025 and sell it today you would lose (57.00) from holding Scinai Immunotherapeutics or give up 43.18% of portfolio value over 90 days. Scinai Immunotherapeutics is currently does not generate positive expected returns and assumes 6.5517% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Scinai, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Scinai Immunotherapeuti Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scinai Immunotherapeuti's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Scinai Immunotherapeutics, and traders can use it to determine the average amount a Scinai Immunotherapeuti's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1002
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCNI |
Based on monthly moving average Scinai Immunotherapeuti is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Scinai Immunotherapeuti by adding Scinai Immunotherapeuti to a well-diversified portfolio.
Scinai Immunotherapeuti Fundamentals Growth
Scinai Stock prices reflect investors' perceptions of the future prospects and financial health of Scinai Immunotherapeuti, and Scinai Immunotherapeuti fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Scinai Stock performance.
| Return On Equity | 0.18 | ||||
| Return On Asset | -0.4 | ||||
| Profit Margin | 4.48 % | ||||
| Operating Margin | (4.87) % | ||||
| Current Valuation | 9.6 M | ||||
| Shares Outstanding | 3.19 M | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 2.08 X | ||||
| Revenue | 658 K | ||||
| Gross Profit | (1.69 M) | ||||
| EBITDA | (6.99 M) | ||||
| Net Income | 4.8 M | ||||
| Cash And Equivalents | 13.45 K | ||||
| Total Debt | 2.09 M | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | 1.47 X | ||||
| Cash Flow From Operations | (6.33 M) | ||||
| Earnings Per Share | 4.00 X | ||||
| Market Capitalization | 2.39 M | ||||
| Total Asset | 13.45 M | ||||
| Retained Earnings | (117.54 M) | ||||
| Working Capital | 585 K | ||||
| Current Asset | 143 K | ||||
| Current Liabilities | 907 K | ||||
About Scinai Immunotherapeuti Performance
By evaluating Scinai Immunotherapeuti's fundamental ratios, stakeholders can gain valuable insights into Scinai Immunotherapeuti's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Scinai Immunotherapeuti has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Scinai Immunotherapeuti has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.01 | |
| Return On Tangible Assets | 0.36 | 0.37 | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | 0.36 | 0.37 | |
| Return On Equity | 0.48 | 0.50 |
Things to note about Scinai Immunotherapeutics performance evaluation
Checking the ongoing alerts about Scinai Immunotherapeuti for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Scinai Immunotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Scinai Immunotherapeuti generated a negative expected return over the last 90 days | |
| Scinai Immunotherapeuti has high historical volatility and very poor performance | |
| Scinai Immunotherapeuti has some characteristics of a very speculative penny stock | |
| Scinai Immunotherapeuti has a very high chance of going through financial distress in the upcoming years | |
| Scinai Immunotherapeutics currently holds 2.09 M in liabilities. Scinai Immunotherapeutics has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Scinai Immunotherapeuti's use of debt, we should always consider it together with its cash and equity. | |
| Scinai Immunotherapeutics currently holds about 13.45 K in cash with (6.33 M) of positive cash flow from operations. | |
| Latest headline from benzinga.com: Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonalds Why These 5 Stocks Are On Investors Radars Today |
- Analyzing Scinai Immunotherapeuti's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Scinai Immunotherapeuti's stock is overvalued or undervalued compared to its peers.
- Examining Scinai Immunotherapeuti's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Scinai Immunotherapeuti's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Scinai Immunotherapeuti's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Scinai Immunotherapeuti's stock. These opinions can provide insight into Scinai Immunotherapeuti's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Scinai Stock analysis
When running Scinai Immunotherapeuti's price analysis, check to measure Scinai Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scinai Immunotherapeuti is operating at the current time. Most of Scinai Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Scinai Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scinai Immunotherapeuti's price. Additionally, you may evaluate how the addition of Scinai Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |